Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 2, 2008, Pages 161-167

  Malan, D R ^a   Krantz, Edrich ^b   David, Neal ^c   Wirtz, Victoria ^d   Hammond, Janet ^d   McGrath, Donnie ^d  

^a Triple M Research   (South Africa)

^b Quinta Med   (South Africa)

^c Brooklyn Medical Centre   (South Africa)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; Atazanavir; HIV; Lamivudine; Ritonavir; Stavudine

Indexed keywords

ATAZANAVIR; RITONAVIR; STAVUDINE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; JAUNDICE; LABORATORY TEST; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OCULOGYRIC CRISIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LIPIDS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OLIGOPEPTIDES; PROSPECTIVE STUDIES; PYRIDINES; RITONAVIR; RNA, VIRAL; STAVUDINE; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 38649100026     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815ace6a     Document Type: Article

References (28)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
2. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, October 10, 2006. Available at: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed March 28, 2007.
3. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-1019.
4. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36:684-692.
5. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273-280.
6. Sension M, Grinsztejn B, Molina J, et al. A1424067: improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline [abstract 858]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
7. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484-1492.
8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
9. Levy AR, McCandless L, Harrigan PR, et al. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis. 2005;4:4.
10. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
11. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
12. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. Available at: http://www.fda.gov/ cder/guidance/3647fnl.htm. Accessed March 28, 2007.
13. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med. 2006;14:125-130.
14. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at 3 doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Kaletra™ USPI, January 2007. Available at: http://www.rxabbott.com/ pdf/kaletratabpi.pdf. Accessed March 28, 2007.
17. Conradie F, Sanne I, Venter W, et al. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004;18:1084-1085.
18. Friend J, Parkin N, Liegler T, et al. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18:1965-1966.
19. Sax PE, Xu F, Tisdale M, et al. First report of development of resistance to boosted fosamprenavir in an ART-naïve subject: virologic and clinical outcome [abstract H-1060]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005; Washington.
20. Agarwala S, Eley T, Filoramo D. Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment-naive HIV-infected patients [abstract 85]. Presented at: Seventh International Workshop on Clinical Pharmacology of HIV Therapy; 2006; Lisbon.
21. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
22. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
23. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
24. - men: changes in practice and Framingham risk scores [abstract 737]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver.
25. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999.
26. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-2614.
27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
28. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.